SSG
NVCR icon

Summit Securities Group’s NovoCure NVCR Stock Holding History

Summit Securities Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-232
Closed -$4.13K – 1316
2025
Q1 		$4.13K Buy
+232
New +$5.27K ﹤0.01% 625
2024
Q2 		– Sell
-251
Closed -$4K – 714
2024
Q1 		$4K Buy
+251
New +$3.69K ﹤0.01% 379

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Summit Securities Group's NVCR Position: Q2 2025 in Review

Summit Securities Group sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 232 shares — an estimated $4.13K sold.

Summit Securities Group first reported a position in NVCR in Q1 2024 and held it in 2 quarters. The position peaked at $4.13K in Q1 2025. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Summit Securities Group reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 232 NovoCure shares in Q2 2025, an estimated $4.13K.
  • Summit Securities Group first reported a position in NovoCure in Q1 2024 and held it in 2 quarters.
  • Summit Securities Group's NovoCure position peaked at $4.13K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.